← Celcuity Inc. (CELC) (CELC) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫
Celcuity Inc. (CELC) (CELC)
Services-Medical Laboratories · market cap $4.0B · as of 2026-07-13
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2026-11-11 (est.)
Earnings
Pipeline
4
programs
Upcoming events
1
next 90d+
Dossier
Ready
cached
Celcuity Inc. (CELC) is a clinical-stage biotech focused on gedatolisib, a pan-PI3K/mTOR inhibitor being evaluated in Phase 3 trials in HR+/HER2- metastatic breast cancer (in combination with CDK4/6 inhibitors and fulvestrant) and metastatic castration-resistant prostate cancer. The company reported two positive Phase 3 readouts on June 30, 2026, driving a market cap of approximately $5.2 billion, though it carries only 7.9 months of cash runway and has no revenue.
The catalyst path
- 2026-11-11 (est.)Earningsimp 5/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| Gedatolisib | Phase 3 | mCRPC (Metastatic Castration-resistant Prostate Cancer) |
| Talazoparib | Phase 2 | TNBC - Triple-Negative Breast Cancer |
| Arm B: Ribociclib + Fulvestrant | Phase 3 | Breast Cancer |
| LY3023414 | Phase 2 | Endometrial Cancer |
Price & technical context
3-month
-30.4%
6-month
-33.5%
12-month
+52.1%
52-wk range
$45.22–$144.98
vs 50-day MA
-14.2%
vs 200-day MA
-28.2%
Realized vol
73.2%
Max drawdown
-49.8%
Daily closes through 2026-10-01. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for CELC (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 4 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.